Rhea-AI Summary
Yumanity Therapeutics announces the completion of its merger with Proteostasis Therapeutics on December 22, 2020, following shareholder approval. Shares will begin trading on Nasdaq under the new ticker symbol YMTX on December 23, 2020. Concurrently, a $33.6 million PIPE transaction was completed. The merger positions Yumanity to advance its clinical programs for neurodegenerative diseases, including Parkinson's disease, with a pipeline that includes YTX-7739 in Phase 1 development. Yumanity anticipates delivering clinical data in 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags